JYMed Technology Co., Ltd. nwere obi ụtọ ịkpọsa na ngwaahịa ya, Tirzepatide, emechaala ndebanye aha Drug Master File (DMF) na US FDA (nọmba DMF: 040115) wee nata nkwenye FDA na August 2, 2024.

Mmepụta Mass na Ọdịmma Stable

Dị ka ndị isi njikwa JYMed Technology si kwuo, nnukwu mmepụta nke Tirzepatide Active Pharmaceutical Ingredient (API) nwere ike iru ọkwa kilogram. Batches mmepụta ahụ kwụsiri ike ma na-aga n'ihu, yana obere mgbanwe dị n'etiti batches, na-eme ka ịdị mma na-agbanwe agbanwe.

Mmetụta dị mkpa na mbelata glucose na lipid

Tirzepatide bụ agonist nnabata GIP/GLP-1 nke izizi n'ụwa otu ugboro kwa izu. Dị ka agonist abụọ na-anabata ya, ọ nwere ike jikọta ma rụọ ọrụ ma onye na-anabata insulinotropic polypeptide (GIP) na-adabere na glucose na onye na-anabata GLP-1 n'ime ahụ mmadụ. Na mgbakwunye na iwetulata ọkwa glucose, ọ na-ebelata oriri oriri, ịdị arọ nke anụ ahụ, na abụba dị n'ime ya, ma na-achịkwa ojiji nke lipid. E wezụga mmetụta ya dị ịrịba ama nke mbelata glucose na mbelata ibu, nyocha nke obere otu sitere na usoro ọmụmụ SURPASS egosila na Tirzepatide na-emeziwanye ihe ngosi metabolic dị ka ọbara mgbali elu, lipids ọbara, BMI, na okirikiri ukwu.

Nkwado mba dị iche iche na atụmanya na-ekwe nkwa

Dịka ozi dabara adaba, Mounjaro na-eweda glucose bụ nke US FDA kwadoro na mbụ na Mee 2022 maka ọgwụgwọ ndị okenye nwere ụdị ọrịa shuga 2. Ọ natala nkwado na EU, Japan na mpaghara ndị ọzọ. Na Nọvemba 2023, FDA kwadoro ihe ngosi mbelata ibu n'okpuru aha aha Zepbound. Na Mee 2024, ọ banyere n'ahịa ndị China nke ọma. N'inyere atụmanya ngwa ya sara mbara yana data nyocha na-akwado siri ike, Tirzepatide abụrụla otu n'ime ọgwụ peptide kachasị ama ama taa. Ahịa ya ruru ijeri $5.163 na 2023, na nkeji mbụ nke 2024 naanị hụrụ ire ere nke ijeri $2.324, na-egosi mmụba dị ịtụnanya.

Banyere JYMed